131265-29-7

Basic information

• Product Name: 8-Benzyloxyadenosine
• Synonyms: 8-Benzyloxyadenosine
• CAS NO: 131265-29-7
• Molecular Weight: 373.368
• Mol File: 131265-29-7.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 8-Benzyloxyadenosine(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Benzyloxyadenosine(131265-29-7)
• EPA Substance Registry System: 8-Benzyloxyadenosine(131265-29-7)

Safety Data

• Hazardous Substances Data: 131265-29-7(Hazardous Substances Data)

Upstream product

• 2946-39-6 8-bromoadenosine 
• 175164-91-7 8-bromo-[2',3',5'-tris-(dimethyl-tert-butylsilyl)]adenosine 
• 100-51-6 benzyl alcohol 

Downstream Products

• 2946-39-6 8-bromoadenosine 
• 131283-75-5 Imidazole-1-carbothioic acid O-[(2R,3S,5R)-5-(6-amino-8-benzyloxy-purin-9-yl)-2-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-3-yl] ester 
• 131707-95-4 (3aR,4R,6R,6aR)-4-(6-Amino-8-benzyloxy-purin-9-yl)-6-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furo[3,4-d][1,3]dioxole-2-thione 
• 131265-38-8 (2R,3S,5R)-5-(6-Amino-8-benzyloxy-purin-9-yl)-2-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-3-ol 
• 131265-45-7 8-Benzyloxy-5'-O-tert-butyldimethylsilyl-2',3'-dideoxyadenosine 
• 127133-07-7 8-Benzyloxy-2',3'-dideoxyadenosine 
• 131265-32-2 (2R,3R,4S,5R)-2-(6-Amino-8-benzyloxy-purin-9-yl)-5-(tert-butyl-dimethyl-silanyloxymethyl)-tetrahydro-furan-3,4-diol 

Relevant articles and documents

Identification of 8-aminoadenosine derivatives as a new class of human concentrative nucleoside transporter 2 inhibitors

Purine-rich foods have long been suspected as a major cause of hyperuricemia. We hypothesized that inhibition of human concentrative nucleoside transporter 2 (hCNT2) would suppress increases in serum urate levels derived from dietary purines. To test this hypothesis, the development of potent hCNT2 inhibitors was required. By modifying adenosine, an hCNT2 substrate, we successfully identified 8-aminoadenosine derivatives as a new class of hCNT2 inhibitors. Compound 12 moderately inhibited hCNT2 (IC50 = 52 ± 3.8 μM), and subsequent structure-activity relationship studies led to the discovery of compound 48 (IC50 = 0.64 ± 0.19 μM). Here we describe significant findings about structural requirements of 8-aminoadenosine derivatives for exhibiting potent hCNT2 inhibitory activity.